Work

New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States

Year: 2025

Type: article

Abstract: Prescriptions made for GLP-1 agonists under various brand names (e.g., Ozempic, Wegovy) have more than tripled since 2020. However, research on their use and their side effects at the population level is in its infancy. This study presents descriptive findings from a 2025 survey fielded to a nationally representative sample of U.S. adults as part of RAND's American Life Panel that show prevalence rates of GLP-1 agonist use and side effects.

Source: Rand health quarterly

DOI: 10.7249/rhq-13-01-03

Authors: Robert Bozick, Shannon Donofry, Katherine Rancaño

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4413022768

FWCI: 3.958

Cites:

Cited by: 7

Related to: 10